Heart failure (HF), known as the terminal stage of various cardiovascular diseases, is characterized by poor prognosis and high mortality. 

JX01 a promising anti-HF drug candidate, showed good pharmacokinetic and safety profiles.

JX01 exhibits better cardiomyocyte protective effects than EMPA in vitro. JX01 exhibits lower minimum effective doses than EMPA in vivo.

JX01 has good pharmacokinetic properties. Pharmacokinetic studies were commissioned by Medicilon.  

Reference:

Yixiang Xu, et al. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria. Acta Pharm Sin B. 2023 Apr;13(4):1671-1685. doi: 10.1016/j.apsb.2022.08.023.